Efficacy

Beleodaq (Belinostat) for the Treatment of Lymphoma

Beleodaq, known by its generic name belinostat, is a histone deacetylase inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). This is a rare type of non-Hodgkin lymphoma that affects the T-cells of the immune system. The efficacy of Beleodaq was evaluated in a multi-center, single-arm clinical trial that involved patients with refractory or relapsed PTCL. Results from this study demonstrated that Beleodaq achieved a 25.8% overall response rate with a median duration of response of 13.6 months, which is significant considering the poor prognosis associated with this disease stage.

The use of Beleodaq has been shown to be beneficial for patients who have limited treatment options. The drug works by interfering with the DNA of cancer cells, leading to cell death. While the response rates do not indicate a cure, they suggest that Beleodaq can provide a meaningful reduction in disease burden and extend progression-free survival in some patients. However, the effectiveness of Beleodaq can vary between individuals, and it is not effective for all patients with PTCL.

Xpovio (Selinexor) for the Treatment of Lymphoma

Xpovio, with the active ingredient selinexor, is another medication that has been granted accelerated approval by the FDA for certain types of lymphoma, including diffuse large B-cell lymphoma (DLBCL), after at least two lines of systemic therapy have failed. Selinexor functions as a selective inhibitor of nuclear export, targeting the exportin 1 (XPO1) protein, which is involved in the transport of many tumor suppressor proteins out of the cell nucleus. By inhibiting XPO1, selinexor can promote the accumulation of tumor suppressor proteins in the nucleus, leading to the suppression of cancer cell growth and induction of apoptosis.

The efficacy of Xpovio in the treatment of DLBCL was assessed in a multicenter, single-arm clinical trial. The trial reported an overall response rate of 28% with a median duration of response of 23 weeks. These results indicate that Xpovio can induce a partial or complete response in a subset of patients with heavily pretreated DLBCL. As with Beleodaq, the response to Xpovio is not universal, and the drug's efficacy may be influenced by various factors, including the genetic characteristics of the lymphoma and previous treatments.